Abstract
Anti-angiogenesis agents (AAs) are widely used in combination with cytotoxic agents for metastatic colorectal cancer (mCRC). Thromboembolism (TE) is an occasional adverse event specific to AAs. Once it occurs during treatment with AAs, discontinuation of AAs is recommended. There are few studies to investigate the clinical course of mCRC after TE during treatment with AAs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
